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Abstract 
Background: The Environmental Exposure Unit (EEU) in Kingston, Ontario, Canada is a controlled allergen challenge 
facility (CACF) that has been previously clinically validated for the use of ragweed and grass pollen in clinical studies. 
In this study we aim to validate the use of birch pollen to challenge allergic participants.
Methods: A total of 59 volunteers were screened and 38 birch allergic participants and ten non-allergics completed 
the study, outside of tree pollen season. Participants had to have a minimum of 2-year history of allergic rhinocon-
junctivitis during the typical tree pollen season and have a positive skin prick test to birch allergen ≥5 mm from the 
control. Qualified participants were exposed to birch (Betula pendula) pollen for 4 h in the EEU and recorded their 
symptoms of sneezing, rhinorrhea, nasal congestion, nasal itch which comprised the total nasal symptom score 
(TNSS), as well as itchy/watery eyes, red/burning eyes and itching of ears/palate/throat which along with the TNSS 
comprised the total rhinoconjunctival symptom score (TRSS) along with Peak Nasal Inspiratory Flow (PNIF) at baseline 
and at 30 min intervals for the duration of exposure, then hourly for up to 12 h from the start of exposure.
Results: Allergic participants reported a gradual rise in TNSS and TRSS, reaching a mean and standard error of the 
mean of 7.08 ± 0.45 and 11.58 ± 0.93 respectively by 180 min from the start of exposure. Symptoms gradually 
declined to near baseline values following departing from the unit, reaching 1.9 and 2.7 by 450 min. Allergic par-
ticipants reported significantly higher TNSS than non-allergics starting from 30 min (p < 0.01, two-way ANOVA with 
Bonferroni corrections), maintaining maximum significance from 60 to 300 min (p < 0.0001) and losing significance by 
420 min. TRSS and PNIF followed similar trends as those seen with TNSS. Participants were phenotyped using previ-
ously published definitions using the TNSS into Early Phase Responders (EPR, 57.8 %), protracted EPR (pEPR, 39.5 %), 
and Dual Phase Responders (DPR, 2.7 %).
Conclusions: The EEU can competently challenge birch allergic participants and achieve statistically significant 
changes in symptoms and nasal airflow, while such changes are not reported in non-allergic controls.
Trial registration NCT02351830 clinicaltrials.gov
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Background
Allergic rhinitis (AR) is an allergen-induced upper respir-
atory inflammatory disease characterized by hyperactive 
airway mucosa resulting in symptoms of rhinorrhea, 
sneezing, nasal pruritus, and congestion, with associated 
symptoms of red, itchy, watery eyes, itching of the palate 
and throat, and cough [1]. AR is widely recognized as the 
most common allergic condition, but detailed estimates 
of its actual prevalence are lacking. Canadian studies 
suggest the life-time prevalence of AR to be between 39 
and 52 % [2]. AR is studied clinically using several types 
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of allergen exposure models that mimic natural exposure 
under controlled conditions. On exposure to allergen, 
study participants experience very similar symptoms to 
those reported during natural exposure.
Studying AR in humans allows for better understand-
ing of the pathophysiology of the disease and provides 
reliable methods for the evaluation of novel therapeutics 
in clinical trials. Nasal allergen challenge (NAC) is one 
method that involves the direct exposure of the nasal 
mucosa to the allergen of interest through a nasal spray 
device, paper discs containing the allergen or sometimes 
through direct pipetting [3]. The NAC method can be 
used in phase 2/3 clinical trials and has proven reliable 
in generating a variety of biological samples for possible 
mechanistic studies of novel medications [4, 5].
Controlled allergen challenge facilities (CACFs), often 
otherwise referred to as “exposure units” or “exposure 
chambers” are specialized units that allow for the simul-
taneous exposure of many participants to controlled 
levels of allergen while also fully controlling the indoor 
air environment, including humidity, temperature, and 
CO2 levels; and additionally provide air filtration [6]. The 
Vienna Challenge Chamber (VCC) in Austria was the 
first multi-participant CACF to be developed in Europe 
[7]. The Environmental Exposure Unit (EEU) at King-
ston General Hospital (KGH) in Kingston, ON, Canada, 
is the first such facility developed in North America and 
can accommodate up to 140 participants per exposure 
visit, and has been established to be a valuable tool in the 
development of several anti-allergic medications (Fig. 1) 
[8–12].
The Environmental Exposure Unit (EEU) operation
The EEU allows for reliable allergen exposure of up to 140 
participants at once while controlling the environment 
regardless of the outdoor weather conditions. A custom-
engineered computer and laser-aided system controls 
the dispersion of a predetermined concentration of pol-
len from a single point of delivery. The pollen is propelled 
using directional fans over the seating area. Rotorod® 
samplers (Sampling Technologies Inc, Minnetonka, Min-
nesota), placed in seven specific locations around the 
seating area, typically sample the pollen in the air every 
30  min, allowing for the assessment of pollen concen-
tration at each location (Fig. 1) [13–15]. Custom micro-
controller regulated rotorods developed by the Allergy 
Research Unit team monitor and transmit their revolu-
tions per minute (RPM) data, along with date and time 
stamp, wirelessly to the research data management sys-
tem, and store information locally on secure digital stor-
age. Sensors that monitor RPM, battery condition and 
rotorod spindle movement provide visual and audible 
feedback on-screen and through warning LED lights as 
well as a speaker in order to be able to alert of any poten-
tial operational issues. If required, environmental sensors 
can be fitted to the microcontroller to provide additional 
point source data of that particular location [15].
Through minor adjustments in the pollen dispersion 
system or directional fans during the exposure visit, pol-
len concentration remains consistent throughout the unit 
[16]. A special ventilation system effectively controls the 
indoor environment, providing 100 % filtered fresh out-
door air, while controlling humidity (adjusted between 
40 and 60 %) and temperature (18–22 °C), and the CO2-
laden air is exhausted outdoors [8]. The system is capable 
of replacing the volume of the room with filtered fresh air 
once every 12 min, while maintaining the pre-set temper-
ature and humidity.
Due to the geographical location of the EEU and the 
high prevalence of ragweed allergy in Kingston, ON, 
ragweed has been extensively used as the allergen of 
Fig. 1 Schematic of the EEU. Gray arrows indicate direction of airflow. 
Adapted with permission from © Ellis et al. [18] licensee BioMed 
Central. 2015
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choice during clinical trials [10, 17, 18]. Recently, there 
has been a growing need to validate and use other aller-
gens for the evaluation of allergen specific immunother-
apies in facilities like the EEU, as opposed to previous 
studies of anti-histamines and intranasal corticoster-
oids, where the specific allergen used is not as critical 
[10, 17–19]. Since different pollens have varying physi-
cal properties such as weight and air dynamics, which 
would affect their suspension in the air and ultimately 
the concentration, there is a need to evaluate the dis-
tribution and clinical effects of different pollens within 
the EEU before incorporating their use into future clini-
cal studies. The use of grass pollen was most recently 
evaluated in the EEU, providing clinical validation of its 
use, and determining the pollen concentration and dis-
tribution requirements needed to reach predetermined 
symptom scores [16].
Ragweed pollen has a barbed and spiky surface giving 
it a “sticky” property and the clumping of pollen grains 
together may cause it to remain aloft during increased air 
current velocities (Fig. 2). Birch pollen, which has a com-
parable particle size to ragweed (20–22 microns com-
pared to 18–20 microns for ragweed), would be expected 
to share similar air suspension characteristics. Having 
three raised pores on its surface, birch pollen may be able 
to remain suspended in the air for longer periods before 
“falling out” of air currents and coming to rest, similar 
to the effect of spikes on ragweed pollen. A birch pol-
len concentration of 3500 ± 500 grains was targeted for 
this study, similar to previous ragweed studies [8]. Pre-
liminary studies in the EEU while fully setup, but without 
human participants, have confirmed the capability of the 
system equipment to release, disperse and maintain birch 
pollen concentrations [20].
We aimed to clinically evaluate the use of European 
White Birch pollen (Betula pendula) to challenge birch 
allergic participants and establish the change in symptom 
scores and nasal air flow at different time points through-
out and following pollen exposure.
Methods
Participants
Individuals on file from previous enrolment in studies 
with the Allergy Research Unit of KGH were approached 
to participate in this study. Inclusion criteria for the 
allergic population included males or females between 
the ages of 18–65 years, a minimum 2 year documented 
history of allergic rhinoconjunctivitis symptoms during 
the typical tree pollen season (mid-April to early June), 
and have a positive skin prick test (SPT) to birch aller-
gen at screening with a wheal diameter ≥5 mm than the 
negative control. Participants had to be willing and able 
to provide written informed consent and comply with 
study requirements. Additionally, sexually active women 
of childbearing potential were asked to use a medically 
acceptable method of birth control, and produce a nega-
tive urine pregnancy test at screening. Non-allergic par-
ticipants had to meet the same criteria except for the 
history of AR and were required to have negative skin 
test responses to a panel of common environmental aller-
gens, including birch.
Exclusion criteria for all participants included having 
an upper respiratory tract infection within 1 week of pol-
len exposure, participants with asthma requiring the use 
of a short-acting beta agonist greater than twice a week, 
or anyone with a history of birch-pollen induced asthma, 
regardless of severity, or a history of any disease that in 
the judgement of the investigator would impact on the 
participant’s safety. Similarly, participants were excluded 
if they had a history of positive test results for Hepati-
tis B, Hepatitis C, HIV, or tuberculosis (other than due 
to vaccination), or significant history of drug or alcohol 
abuse or other clinically relevant abnormalities on physi-
cal exam. Other exclusion criteria were females who were 
pregnant, actively trying to become pregnant, or cur-
rently lactating. Participants were also asked to observe 
washout periods for medications listed in Table 1.
The study was reviewed and ethics clearance granted 
by the Queen’s University and Affiliated Teaching Hospi-
tals Research Ethics Board (REB), and was registered at 
clinicaltrials.gov (NCT02351830).
Study design
The study was conducted outside of pollen season (Feb-
ruary 2015). At the screening visit, participants provided 
written informed consent and had their vital signs, height 
and weight measured. A medical history was taken and 
physical examination, including nasal examination, was 
conducted. SPT was performed on the volar surface of 
the participant’s forearm for the following allergens: 
Fig. 2 Topographic features of birch and ragweed pollen on micro-
scopic examination (not to scale). Birch pollen (left) have smoother 
surfaces with three pores compared to ragweed pollen which have 
spiky and barbed surfaces that causes the pollen grain to clump 
together. Both pollen are of comparable size, 20–22 microns in the 
case of birch pollen and 18–20 microns for ragweed pollen
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Birch, timothy grass, rye grass, short ragweed, tree mix, 
dog, cat, dust mite (D. pteronyssinus, D. farinae), and 
Alternaria mould.
Qualified participants were invited back to the EEU for 
one 4 h birch pollen exposure session. Before the expo-
sure, the inclusion and exclusion criteria were reviewed 
and an infectious disease questionnaire was completed 
by the participants to ensure they were in good health. 
Women of childbearing potential were required to have a 
negative pregnancy test.
Participants were seated inside the EEU and birch pol-
len (Greer, NC) was delivered and maintained at a con-
centration of 3500 ± 500 grains. The pollen concentration 
was determined every 30 min using seven Rotorod® sam-
plers placed at specific locations and the pollen emission 
rate was then modified based on the Rotorod® counts 
to maintain equal distribution of the pollen throughout 
the facility. Other environmental factors were controlled 
during the exposure period as described earlier.
Participants used either paper diary cards or elec-
tronic tablets [21] to record their total nasal symptom 
score (TNSS) at baseline and at 30 min intervals for the 
duration of the exposure, then hourly up to 12  h from 
the start of pollen exposure. Participant symptoms were 
captured using both paper diary cards and as electronic 
patient-reported outcomes (ePRO) recorded on tab-
lets. Both means to capture the participants’ symptoms 
resulted in data being stored in our validated Clini-
cal Trial Data Management System. All participants 
recorded their symptoms from hours 4–12 on paper 
diary cards and mailed them back to the site upon 
completion. At each time point participants graded their 
symptoms on a scale from 0 to 3, including sneezing, 
runny nose, itchy nose, and congestion, for a total out of 
12 (Table 2). Participants also recorded ratings of symp-
tom severity for itchy ears/palate/throat, itchy/gritty 
eyes, red/burning eyes, and teary eyes, and these scores, 
in addition to the TNSS, comprised the Total Rhinocon-
junctivitis Symptom Score (TRSS) for a maximum score 
of 24. Participants were trained to measure peak nasal 
inspiratory flow (PNIF) using a facial mask and meter 
(InCheck, Clement Clarke International Ltd, Essex, 
UK), taking three measurements at each time point. The 
greatest of the three measurements was used as the final 
measure of air flow.
Biological samples were collected during this study, 
including nasal brushing for sampling epithelial cells and 
blood samples for PAX gene analysis and CBC differen-
tials. The results from these analyses will be reported in 
future submissions.
Statistical analysis
GraphPad Prism 6.0 (San Diego, CA, USA) was used for 
the statistical analysis of the data. TNSS, TRSS, and PNIF 
data from allergic and non-allergic participants were 
compared using two-way repeated measures ANOVA 
with Bonferroni’s correction. Comparisons of scores at 
different points to baseline was completed using one-way 
repeated measures ANOVA with Tukey’s correction. The 
percentage reduction in PNIF at each time point com-
pared to baseline was used to compare allergic and non-
allergic groups.
Results
Fifty-nine volunteers were screened for enrollment; a 
total of 38 birch allergic and ten non-allergic participants 
completed the study; one allergic participant failed to 
return all the take-home diary cards and was excluded 
from the analysis. A further four participants neglected 
to record PNIF values on the diary cards completed 
after leaving the EEU and were thus excluded from the 
Table 1 Washout periods for medications
Participants were asked to follow the washout periods of the medications below 
before the pollen exposure visit
a Hydrocortisone ≤1 % used on <10 % body surface area was permitted 
throughout the study
Medication Duration of washout prior 
to the pollen exposure visit
Beta-blockers, alpha-adrenoceptor 
blockers, currently receiving allergen 
immunotherapy
Not permitted
Topical alpha-adrenergic agonists 48 h
H1 receptor antagonists 7 days
Topical corticosteroidsa 7 days
Anticholinergics 7 days
Intranasal or inhaled corticosteroids 14 days
Intranasal or inhaled cromolyn 14 days
Tricyclic antidepressants and monoam-
ine oxidase inhibitors
14 days
Leukotriene inhibitors 14 days
Systemic corticosteroids (oral) 30 days
Depot corticosteroids 60 days
Table 2 Symptom score definitions
Participants graded each symptom on a 3-point Likert scale (0–3) every 30 min. 
The total score was added up for a total out of 12 (TNSS) and 24 (TRSS)
Score Definition
0 = none Symptom is completely absent
1 = mild Symptom is present but minimal awareness, easily 
tolerated
2 = moderate Awareness of symptoms, bothersome, but tolerable and 
not interfering with daily activities
3 = severe Definite awareness of symptoms, difficult to tolerate, 
interferes with activities; and/or desires treatment
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PNIF analysis. Prior to pollen exposure, TNSS, TRSS and 
PNIF recordings were similar for both allergic and non-
allergic groups with no statistical difference (Figs.  3, 4). 
Allergic participants experienced a gradual rise in TNSS 
and TRSS, reaching a mean score and standard error of 
the mean of 7.08 ± 0.45 and 11.58 ± 0.93 respectively at 
180 min from the start of exposure, and maintained this 
level until the end of the visit at 240 min. TNSS and TRSS 
gradually declined after leaving the EEU, up to 450 min 
from the start of the study at which point both symp-
tom scores reached a nadir of 1.9 ± 0.32 and 2.7 ± 0.49 
respectively (Fig. 3).
Non-allergic participants reported no change in their 
symptoms over the entire duration of the study. Aller-
gic participants reported statistically higher TNSS than 
non-allergic participants at most time points, start-
ing from the 30 min time point (p < 0.01), reaching and 
maintaining maximum significance from 60 to 300  min 
(p < 0.0001), declining gradually until 420 min at which 
statistical significance was lost (Table 3). TRSS followed a 
similar trend (Fig. 3; Table 3).
Within the allergic participants, the rapid increase 
in TNSS was statistically significant compared to their 
baseline measurements at all time points (Table  3). 
A similar trend was observed with TRSS while no 
such significant change was reported by non-allergic 
participants.
PNIF recorded by allergic participants followed a 
similar trend to TNSS and TRSS, though nasal air flow 
never returned to baseline values by the end of the study 
period (Fig.  4). While non-allergic participants experi-
enced no statistically significant change in PNIF com-
pared to baseline, birch allergic participants reported a 
significant reduction in their PNIF at most time points 
(Table 3).
The percentage change in PNIF from baseline is 
another method used to analyze nasal air flow, provid-
ing further comparison between allergic and non-allergic 
participants. Non-allergic participants recorded greater 
variability in PNIF Due to this variability, it was difficult 
to compare allergic to non-allergic participants, though 
the difference in pattern was visually apparent.
Participants were phenotyped according to their 
TNSS pattern using previously defined and published 
definitions (Fig.  5) [22]. Twenty-two participants 
(57.8  %) experienced a gradual rise in their TNSS fol-
lowed by a reduction of 50  % from the peak score 
by the 6th or 7th  hour and were classified as Early 
Phase Responders (EPR). Fifteen participants (39.5  %) 
reported a similar gradual rise in symptoms but did not 
experience a reduction of 50 % in symptoms by the 6th 
or 7th hour, and were classified as having a protracted 
EPR (pEPR). One sole participant in this study met the 
criteria for a Dual Phase Responder (DPR), in that they 
experienced a 50  % reduction in TNSS by the 6th or 
7th hour followed by an increase of at least two points 
thereafter.
Fig. 3 Increase in TNSS and TRSS reported by birch allergic par-
ticipants during the EEU challenge visit. Birch allergic participants 
reported a gradual increase in total nasal symptom scores (TNSS) and 
total rhinoconjunctivitis symptom scores (TRSS), reaching a maxi-
mum of 7 and 11.6 respectively at 180 min, and sustaining this level 
until the end of the exposure period at 240 min. Symptoms gradually 
returned to near baseline values following the end of exposure. 
Non-allergic participants did not report such changes and had no 
statistically significant increase in scores from baseline
Fig. 4 Decrease in PNIF reported by birch allergic and non-allergic 
participants during the EEU challenge visit. Birch allergic participants 
experienced a reduction in their peak nasal inspiratory flow (PNIF) 
compared to baseline, which was sustained for the duration of the 
exposure period (up to 240 min time point) and peaking at a mean 
reduction of 28.6 % at 210 min. The PNIF gradually decreased fol-
lowing the challenge but did not return to baseline values by the 
480 min time point. Non-allergic participants reported wide variation 
in their PNIF but with no statistically significant change from baseline 
values throughout the duration of the study (one-way repeated 
measures ANOVA with Tukey’s correction). NB: four participants did 
not complete the PNIF section of the diary cards they took home 
(270 min time point to 480 min) and were excluded from this analysis
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Discussion
Birch allergic participants were clearly able to experience 
symptoms of AR due to controlled birch pollen challenge 
in the EEU outside of tree pollen season. The symptoms 
experienced were statistically higher than that experi-
enced by non-allergic participants, the majority of whom 
experienced no symptoms at all. The single 4-h session 
was also able to elicit eye-related symptoms of allergic 
conjunctivitis. Accompanying the development of rhi-
nitis symptoms, participants experience a significant 
reduction in nasal air flow.
The results from the study suggest that the birch pollen 
concentration of 3500 ± 500 grains was an adequate con-
centration to target and produced the intended results 
in a period of time mirroring a ragweed exposure. This 
may be attributed to similarities in topography and size 
between ragweed and birch pollen, and as such the target 
concentration used for ragweed studies was also appro-
priate for this study using birch pollen.
Participants in this study demonstrated a variety of AR 
phenotypes, allowing for the future study of the effect of 
novel therapies in each of EPR, pEPR and DPR. It was 
noteworthy that challenge with birch pollen appears to 
be associated with a lower rate of DPR generation than 
Table 3 Statistically significant change in  TNSS, TRSS, 
and PNIF when comparing allergic and non-allergic partic-
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Allergic participants reported statistically significant increase in TNSS and TRSS 
and reduction in PNIF compared to non-allergic participants at most time 
points. Within the allergic group, changes in TNSS and PNIF, following allergen 
exposure, was significantly different from baseline measurements
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seen previously following a ragweed allergen challenge 
[22]. Overall, however, the distribution of participants 
demonstrating the different phenotypes is similar to pre-
viously published data using ragweed allergen to chal-
lenge participants at the EEU [22].
One observed difference between the current study and 
our previous investigation involving a ragweed challenge 
is the slightly lower peak TNSS in the birch evaluation; 
a mean peak TNSS of 9.2 was observed in the ragweed 
study [17] compared to 7.1 in the birch study. The study 
that validated the EEU for grass pollen challenges also 
yielded slightly different responses to our current evalu-
ation. This study was of a slightly different design, and 
challenged participants over two consecutive days for 
3  h to evaluate effects of repeated exposures [16]. As a 
result of this “priming” effect, a mean peak TNSS of 9.2 
was reached on the second day. The single birch pollen 
exposure session in this study, while resulting in a lower 
mean peak TNSS (7.1) was still enough to achieve and 
exceed the typical target TNSS of 6 often used for CACF 
type studies [23–26]. Higher scores might be achieved, if 
needed, by adding priming sessions to “re-awaken” the 
allergic reaction to pollen when studying AR outside of 
the relevant pollen season [6, 27].
Conclusions
The EEU provides a controlled environment for effec-
tively studying birch induced AR outside of the pollen 
season, adding to the previous toolkit of ragweed and 
grass pollen challenge expertise. Such capability allows 
for the testing of allergen specific novel immunotherapies 
in a controlled environment while accommodating up to 
140 participants per study session.
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